Trials / Completed
CompletedNCT00274313
Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients
A Study of the Safety and Pharmacokinetics of 552-02 Following 14 Days of Dosing By Inhalation in Patients With Cystic Fibrosis
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Parion Sciences · Industry
- Sex
- All
- Age
- 14 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of a new inhaled sodium-channel blocker called 552-02 in teens and adults with cystic fibrosis. 552-02 will be inhaled once a day for 14 days using a nebulizer. A small subgroup of patients will donate blood samples for pharmacokinetic analysis to see how 552-02 is absorbed into the blood and eliminated after 14 days of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 552-02 |
Timeline
- Start date
- 2006-01-01
- Completion
- 2006-08-01
- First posted
- 2006-01-10
- Last updated
- 2009-01-14
Locations
15 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00274313. Inclusion in this directory is not an endorsement.